Harvard Health Letter

Combination therapy may be better for one common lung cancer

For people with non-small cell lung cancer that carries a mutation in the gene KRAS, a combination of the drug selumetinib and the chemotherapy drug docetaxel may be more effective than chemotherapy alone.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »